LVLee C. Vermeulen

Lee C. Vermeulen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lee C. Vermeulen has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • James M. Hoffman

    Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN, USA

    3 shared publications
  • Eric A. Geurkink

    2 shared publications
  • Marianne F. Ivey

    James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH

    2 shared publications
  • Nilay D. Shah

    Division of Health Care Policy and Research, Mayo Clinic College of Medicine, Rochester, MN, and Associate Consultant, Mayo Clinic, Rochester

    2 shared publications
  • Robert J. Hunkler

    Professional Relations, IMS Health, Plymouth Meeting, PA

    2 shared publications
  • Stephanie N. Davis

    Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison 53792, USA

    2 shared publications

Latest Publications

  • Revision of the International Pharmaceutical Federation’s Basel Statements on the future of hospital pharmacy: From Basel to Bangkok

    by Lee C. Vermeulen, Rebekah J. Moles, Jack C. Collins, Andy Gray, Abdul Latif Sheikh, Jacqueline Surugue, Robert J. Moss, Marianne F. Ivey, James G. Stevenson, Yasuo Takeda, et al.

    Purpose The processes used to revise the 2008 Basel Statements on the future of hospital pharmacy are summarized, and the revised statements are presented. Methods The process for revising the Basel Statements followed an approach similar to that used during their initial development. The Hospital Pharmacy Section (HPS) of the International Pharmaceutical Federation (FIP) revised the 2008 FIP Basel Statements in four phases, including a survey of hospital pharmacists worldwide, an internal review, online forums, and a face-to-face “World Café” workshop in Bangkok, Thailand. Results The global survey on the initial Basel Statements included input from 334 respondents from 62 countries. The majority of respondents agreed that most of the initial Basel Statements were acceptable as written and did not require revision. In total, 11 statements were judged by more than 10% of respondents as needing revision or deletion. The FIP HPS executive committee used the survey results to develop 69 initial revised draft statements. After an online discussion with the international hospital pharmacy community, including individuals from 28 countries representing all six World Health Organization regions, a final set of draft statements was prepared for the live discussion involving participants from 20 countries. The final 65 revised Basel Statements were voted on and accepted. Conclusion Systematic revision of the FIP Basel Statements resulted in an updated reflection of aspirational goals for the future of hospital pharmacy practice. While this revision reflects the development of new goals for hospital pharmacy practice, the core principles of the Basel Statements remain an essential foundation for the discipline.


  • Open Access

    Comparison Friction: Experimental Evidence from Medicare Drug Plans

    by Jeffrey R. Kling, Sendhil Mullainathan, Eldar Shafir, Lee C. Vermeulen, Marian V. Wrobel

    Consumers need information to compare alternatives for markets to function efficiently. Recognizing this, public policies often pair competition with easy access to comparative information. The implicit assumption is that comparison friction—the wedge between the availability of comparative information and consumers' use of it—is inconsequential because when information is readily available, consumers will access this information and make effective choices. We examine the extent of comparison friction in the market for Medicare Part D prescription drug plans in the United States. In a randomized field experiment, an intervention group received a letter with personalized cost information. That information was readily available for free and widely advertised. However, this additional step—providing the information rather than having consumers actively access it—had an impact. Plan switching was 28% in the intervention group, versus 17% in the comparison group, and the intervention caused an average decline in predicted consumer cost of about $100 a year among letter recipients—roughly 5% of the cost in the comparison group. Our results suggest that comparison friction can be large even when the cost of acquiring information is small and may be relevant for a wide range of public policies that incorporate consumer choice.


  • Projecting future drug expenditures—2010

    by James M. Hoffman, Fred Doloresco, Lee C. Vermeulen, Nilay D. Shah, Linda Matusiak, Robert J. Hunkler, Glen T. Schumock

    Purpose Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed. Summary Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008. Conclusion In 2010, we project a 3–5% increase in drug expenditures in outpatient settings, a 6–8% increase in expenditures for clinic-administered drugs, and a 2–4% increase in hospital drug expenditures.


  • Strategic approach for improving the medication-use process in health systems: The high-performance pharmacy practice framework

    by Lee C. Vermeulen, Steve S. Rough, Thomas S. Thielke, Rita R. Shane, Marianne F. Ivey, Billy W. Woodward, Paul G. Pierpaoli, Sylvia M. Thomley, Christopher A. Borr, David A. Zilz

    Purpose. A strategic approach to improving the medication-use process in health systems by using a framework for setting priorities on the basis of feasibility, the potential for financial return, and the effect on quality and safety is described.


    • 1 September 2006
      • Vol. 105  (6) , 19-20

    Medication costs in Wisconsin Medicaid: Waste not, want not?

    by Lee Vermeulen

  • Open Access

    Projecting future drug expenditures—2005

    by James M. Hoffman, Nilay D. Shah, Lee C. Vermeulen, Robert J. Hunkler, Karrie M. Hontz

    Purpose. Drug expenditure trends in 2003 and 2004 and projected drug expenditures for 2005 are discussed. Summary. Various factors are likely to affect drug costs, including drug prices, drugs in development, and generic drugs. In 2003 there was a continued moderation of the increase in drug expenditures. Drug expenditures increased by 11.4% from 2002 to 2003. Through the first nine months of 2004, expenditures increased by only 8.7% compared with 2003. This moderation can be attributed to many factors, particularly patent expirations, prescription-to-nonprescription conversions, and a continued slowdown in new drug approvals. Higher cost sharing for consumers and continued weaknesses in several sectors of the U.S. economy affecting employment levels and insurance coverage also contributed to this smaller increase in drug utilization. It is expected that 2005 drug expenditure growth will outpace the growth in overall health care expenditures and growth in the economy. Conclusion. In 2005, there should be a 10–12% increase in drug expenditures in outpatient settings, a 12–15% increase in clinics, and a 6–9% increase in hospitals.


  • Open Access

    Pharmacy residency training in academic medical centers

    by James M. Hoffman, Sylvia Thomley, Lee Vermeulen, Kelly M. Smith

    Purpose. A survey of U.S. academic medical centers (AMCs) was conducted to identify the most important and challenging issues in pharmacy residency training. Methods. A questionnaire addressing program characteristics and residency training concerns was sent electronically to pharmacy directors at 130 AMCs that are members or associate members of the University HealthSystem Consortium (UHC). Residency coordinators for both pharmacy practice and specialized programs were asked to complete the questionnaire, with input from other pharmacists involved in the residency program. Respondents were asked to rate the importance and degree of challenge for all issues on a 5-point Likert scale, where 1 = least important or least challenging and 5 = most important or most challenging. Results. Responses were received from hospitals representing over 60% of all residency positions offered by UHC member hospitals. Recruitment was rated the most important issue (mean importance score, 4.8) facing residency programs in AMCs, but with over 85% of budgeted positions filled, programs appear to be successful in overcoming this concern. The most challenging issue (mean challenge score, 4.2) was compliance with the evaluation and documentation elements of the ASHP Residency Learning System (RLS), a system often used to meet requirements for pharmacy practice residency accreditation. The completion of resident research requirements was ranked as both an important and a challenging issue (mean importance score, 4.5; mean challenge score, 3.9). Conclusion. A survey of AMCs showed that they offered a wide variety of pharmacy residency programs and filled most budgeted resident positions. Resident recruitment, the RLS, and research requirements are the most important and challenging residency concerns facing the respondents.


  • Open Access

    Clinical and Humanistic Outcomes in Patients With Gastroesophageal Reflux Disease Converted From Omeprazole to Lansoprazole

    by Winnie W. Nelson, Lee C. Vermeulen, Eric A. Geurkink, David A. Ehlert, Mark Reichelderfer

    TWO PROTON pump inhibitors (PPIs), lansoprazole (Prevacid; TAP Pharmaceuticals Inc, Deerfield, Ill) and omeprazole (Prilosec; AstraZeneca, Wayne, Pa), are currently available commercially in the United States. Both agents are approved by the Food and Drug Administration for the treatment of duodenal and gastric ulcer, gastroesophageal reflux disease (GERD), eradication of Helicobacter pylori, and pathologic hypersecretory conditions. Lansoprazole is also approved for the prophylaxis of duodenal ulcer. In clinical trials, both agents have shown comparable safety and efficacy in treating acid-related peptic disorders.1-3 In the treatment of GERD, a condition that requires prolonged gastric acid suppression, PPIs were found to be effective 78% to 90% of the time.4,5